ANNUAL MEETING EDUCATIONAL OBJECTIVES - PARTICIPANTS WILL BE ABLE TO: •  Learn new pharmacoeconomic and outcomes research methodologies. •  Improve the quality of healthcare decision-making by using the results of pharmacoeconomic and outcomes research. •  Learn more about measuring quality-of-life, willingness-to-pay, patient preferences, and other utility measures. ISPOR MISSION The ISPOR mission is to translate pharmacoeconomics and outcomes research into practice. We encourage health care practitioners, health care purchasers, health care decision-makers as well as pharmacoeconomic and outcomes researchers to attend this meeting.

Monday, May 22, 2000

8:00-8:10AM		WELCOME Gerry Oster PhD, Vice President, PAI, Brookline, MA, USA and General Chair, ISPOR Fifth Annual International Meeting Planning Committee
8:10-8:30AM		PRESIDENTIAL ADDRESS Bryan R. Luce PhD, MBA, Senior Research Leader & CEO, MEDTAP International, Bethesda, MD, USA and ISPOR 1999-2000 President
8:30-10:00AM		FIRST PLENARY SESSION Pharmacoeconomics and Outcomes Research in the New Millennium Moderator: Gerry Oster PhD, Vice President, PAI, Brookline, MA, USA "A US Perspective on the Future of Pharmacoeconomics and Outcomes Research" John M. Eisenberg MD, MBA, Administrator, Agency for Health Care Policy & Research, Department of Health & Human Services, Rockville, MD, USA "The Future of Pharmacoeconomics and Outcomes Research: Will the Bubble Burst? A European Perspective" Michael Drummond Mcom, Dphil, Director, Centre for Health Economics, University of York, York, UK
10:00-10:30PM		VIEWING OF POSTER PRESENTATIONS & EXHIBITS IN EXHIBIT AREA
10:30-12:00PM		CONTRIBUTED WORKSHOP PRESENTERS MEETING
10:30-12:00PM		CONTRIBUTED PODIUM PRESENTATIONS
		DECISION ANALYTIC MODELING
	D1	DEVELOPMENT AND VALIDATION OF A SCREENING INSTRUMENT FOR GASTROESOPHAGEAL REFLUX DISEASE (GERD) Fullerton S1, Emery K1, Reyes E1, Lee J1, Shaw M2, Shafiroff J1, Willian MK3, Grogg A3, Sadik K3, Ofman J1, 1Zynx Health Inc., Beverly Hills, CA, USA; 2Cedars-Sinai, Department of Health Services Research, Beverly Hills, CA, USA; 3Janssen Pharmaceutica Inc., Titusville, NJ, USA
	D2	COST UTILITY OF DOCETAXEL VS VINORELBINE OR PACLITAXEL IN ADVANCED BREAST CANCER Brown R1, Hutton J2, 1MEDTAP International Inc., Bethesda, MD, USA; 2MEDTAP International Inc., London, UK
	D3	A PHARMACOECONOMIC MODEL TO ASSESS THE COST-EFFECTIVENESS OF TROVAFLOXACIN COMPARED TO CEFTAZIDIME FOR NOSOCOMIAL PNEUMONIA IN A PUBLIC HOSPITAL SETTING IN HONG KONG Lee KKC1, You JHS1, Ho SSS1, Chan TYK2, 1Departments of Pharmacy, The Chinese University of Hong Kong, Shatin, Hong Kong, China; 2Medicine & Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong, China
	D4	ECONOMIC ANALYSIS OF WARFARIN IN OUTPATIENTS WITH ATRIAL FIBRILLATION: INNOVATOR VERSUS GENERIC Mittmann N1, Bartle W2, Walker SE2, Oh PI1, 1HOPE Research Centre, Sunnybrook And Women's College Health Sciences Centre, University of Toronto, Toronto, ON, Canada; 2Department of Pharmacy, Sunnybrook and Women's College Health Sciences Centre, University of Toronto, Toronto, ON, Canada
		RETROSPECTIVE DATABASE ANALYSES
	R1	QUANTIFYING THE IMPACT OF INTERACTIONS BETWEEN HMG-COA REDUCTASE INHIBITORS (STATINS) AND CYTOCHROME P-450 INTERACTING DRUGS ON HEALTHCARE UTILIZATION: A POPULATION-BASED STUDY Iskedjian M1, Metge CJ2, Einarson TR13, Yogendran M2, Mukherjeee J4, 1PharmIdeas Research and Consulting Inc., Hamilton, ON, Canada; 2University of Manitoba, Winnipeg, MB, Canada; 3University of Toronto, Toronto, ON, Canada; 4Bristol-Myers Squibb Canada, Montreal, QC, Canada
	R2	RISK FACTORS FOR SHORT-TERM DIABETES COMPLICATIONS: AN ANALYSIS OF LINKED ADMINISTRATIVE CLAIMS AND CLINICAL LABORATORY DATA Menzin J1, Boulanger L1, Friedman M1, Langley-Hawthorne C2, 1Boston Health Economics, Inc., Billerica, MA, USA; 2ManagedEdge, Oakland, CA, USA
	R3	DONEPEZIL USE AND IMPACT ON COST AMONG PATIENTS WITH ALZHEIMER'S DISEASE West WA, Prashker M, Merriman L, Anderson J, Miller D, Center for Healthcare Quality, Outcomes, and Economic Research, Bedford, MA, USA
	R4	AVAILABILITY OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY ASSOCIATED WITH INCREASED SURVIVAL AND LOWER COSTS AT A VA MEDICAL CENTER McCollum M1, Malone DC2, MaWhinney S3, Bessesen M4, 1School of Pharmacy, University of Colorado Health Sciences Center, Denver, CO, USA; 2College of Pharmacy, University of Arizona, Tucson, AZ, USA; 3Department of Preventive Medicine and Biometrics, University of Colorado, Health Sciences Center, Denver, CO, USA; 4Infectious Disease Section, Denver VA Medical Center, Denver, CO, USA
		DRUG USE AND HEALTHCARE POLICY RESEARCH
	DH1	AN ANALYSIS OF THE IMPACT OF MEDICATION NON-ADHERENCE AND TYPE OF MEDICATION ON OUTCOME DOMAINS USING THE SCAP HEALTH QUESTIONNAIRE Russo P, Dirani R, The MEDSTAT Group, Inc., Washington, DC, USA
	DH2	MEDICARE'S EXTENDED IMMUNOSUPPRESSION COVERAGE IMPROVED MIDDLE-INCOME RENAL GRAFT SURVIVAL Woodward RS1, Schnitzler MA1, Hollenbeak CS1, Lowell JA1, Singer GG1, Cohen DS1, Spitznagel EL2, Brennan DC1, 1Medical School, Washington University, St. Louis, MO, USA; 2Mathematics Department, Washington University, St. Louis, MO, USA
	DH3	PUBLIC REPORT SPURS HOSPITAL MORTALITY REDUCTION Czerwinski AA, Horgan MM, Care Management Science Corporation, Philadelphia, PA, USA
	DH4	SCHIZOPHRENIA CARE AND ASSESSMENT PROGRAM (SCAP): IMPACT OF CLINICAL AND FUNCTIONAL STATUS AND TYPE OF MEDICATION TREATMENT ON OUTPATIENT PSYCHIATRIC UTILIZATION Russo P, Dirani R, Smith M, The MEDSTAT Group, Inc., Washington, DC, USA
		QUALITY-OF-LIFE EVALUATIONS
	Q1	CONSUMER AND STAFF VALIDATION OF A SELF-ADMINISTERED HEALTH-RELATED QUALITY OF LIFE INSTRUMENT FOR INDIVIDUALS WITH SCHIZOPHRENIA Barr JT1, Schumacher GE1, Mason EJ1, Ohman SM1, Hanson A2, 1Northeastern University, School of Pharmacy, Boston, MA, USA; 2Massachusetts Division of Medical Assistance, Boston, MA, USA
	Q2	PATIENT PREFERENCES FOR TREATMENT OUTCOMES IN DISABLING TREMOR Leidy NK1, Palmer C1, Coughlin C2, Halpern M1, Charles D3, 1MEDTAP International, Bethesda, MD, USA; 2Ingenix, Eden Prairie, MN, USA; 3Vanderbilt University, Nashville, TN, USA
	Q3	HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN AFRICAN AMERICAN MEN WITH PROSTATE CANCER: DATA FROM CaPSURE Lubeck DP1, Grossfeld G1, Ray P2, Flanders SC3, Carroll PR1, 1Department of Urology, University of California, San Francisco, CA, USA; 2Cook County Hospital, Chicago, IL, USA; 3TAP Holdings, Deerfield, IL, USA
	Q4	MINIMUM MEANINGFUL DIFFERENCE SCORES FOR THE IRRITABLE BOWEL SYNDROME QUALITY OF LIFE QUESTIONNAIRE (IBSQOL) Watson ME, Glaxo Wellcome, Research Triangle Park, NC, USA
12:00-1:00PM		LUNCH, EXHIBITS, AND POSTER VIEWING
1:00-2:30PM		ISSUE PANELS (4 concurrent discussions)
		To P or Not to P: Significance Testing and Confidence Intervals in Outcomes Research Discussion Leader: Joseph Heyes PhD, Executive Director, Biostatostics and Research Data Systems, Merck Research Laboratories, Blue Bell, PA, USA Incorporation of Non-Medical Costs in Cost-Effectiveness Analysis: A Practical Guide Discussion Leader: Bernard Bloom PhD, Research Professor, University of Pennsylvania, Philadelphia, PA, USA Is There Utility to Utilities? Discussion Leader: Bernie O'Brien PhD, BA, MSc, Associate Professor, McMaster University, Department of Clinical Epidemiology & Biostatistic, Hamilton, ON, Canada The Role of Consumers in Medical Decision Making Discussion Leader: Myrl Weinberg CAE, President, National Health Council, Washington, DC, USA
2:30-3:30PM		VIEWING OF CONTRIBUTED POSTER PRESENTATIONS, SESSION I
3:30-4:30PM		CONTRIBUTED WORKSHOPS (concurrent presentations)
	WW1	IDENTIFYING THE IMPACT OF A TREATMENT ON OUTCOMES AND COSTS USING OBSERVATIONAL DATA: OVERCOMING SELECTION BIAS Polsky D, Glick H, School of Medicine and Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA, USA
	WW2	DEVELOPMENT OF INTERNET-CAPABLE INSTRUMENTS FOR MEASUREMENT OF UTILITIES Lenert LA12, 1Veterans Administration San Diego Healthcare System, San Diego, CA, USA; 2University of California at San Diego, San Diego, CA, USA
	WW3	THE ROLE OF VALIDATION STUDIES IN SUPPORTING RETROSPECTIVE COST-OF-ILLNESS EVALUATIONS Menzin J, Lang K, Boston Health Economics, Inc., Billerica, MA, USA
	WW4	ESTIMATING LIFE-YEARS GAINED FROM INCOMPLETE DATA Caro J, Klittich W, Huybrechts K, Caro Research, Concord, MA, USA
	WW5	CONCOMITANT MEDICATION COSTING USING CLINICAL TRIAL DATA: A CASE STUDY Neighbors D, Candrilli S, Research Triangle Institute, Research Triangle Park, NC, USA
	WW6	BEING PRAGMATIC ABOUT THE DESIGN AND EXECUTION OF PRAGMATIC TRIALS Drummond M12, Torrance G23, Walker V2, 1Centre for Health Economics, University of York, York, UK; 2Innovus Research Inc., Burlington, ON, Canada; 3McMaster University, Hamilton, ON, Canada
	WW7	REALITY CHECK - DEFINING AND MEETING THE PRACTICAL NEEDS OF PAYERS WITH HEALTH ECONOMIC EVALUATION Bentkover JD1, Wierz DJ2, Stewart EJ1, 1Innovative Health Solutions, Brookline, MA, USA; 2Wyeth-Ayerst Pharmaceuticals, St. Davids, PA, USA
	WW8	BAYESIAN METHODS FOR COST-EFFECTIVENESS ANALYSIS O'Hagan A1, Stevens JW2, Luce B3, 1University of Sheffield, Sheffield, UK; 2AstraZeneca R&D Charnwood, Loughborough, UK; 3MEDTAP International, Bethesda, MD, USA
4:30-5:30PM		CONTRIBUTED WORKSHOPS (concurrent presentations)
	WW9	RANDOMIZATION, BEHAVIOR AND BIAS: REEVALUATING THE PREFERENCE FOR RANDOMIZED TREATMENT ASSIGNMENTS Dulisse B, Statistical and Mathematical Sciences, Lilly Research Labs, Eli Lilly & Co., Indianapolis, IN, USA
	WW10	THE "BIG MAC INDEX" FOR HEALTH CARE: A SOLUTION TO EXTRAPOLATION HEADACHES? Caro J, Huybrechts K, Klittich W, Caro Research, Concord, MA, USA
	WW11	USING STATED PREFERENCE INFORMATION IN RANDOMIZED CLINICAL TRIALS TO ASSESS BENEFITS OF NEW PHARMACEUTICALS Teague J, Bingham M, Triangle Economic Research, Durham, NC, USA
	WW12	SPECIFICATION ISSUES IN OUTCOMES MODELS Crown WH, The MEDSTAT Group, Cambridge, MA, USA
	WW13	MODELING IN ECONOMIC EVALUATION: CALIBRATION, CORROBORATION AND VALIDATION Weinstein MC12, Grima DT3, 1Center for Risk Analysis, Harvard School of Public Health, Boston, MA, USA; 2Innovus Research, Inc., Medford, MA, USA; 3Innovus Research, Inc., Burlington, ON, Canada
	WW14	SELECTING HEALTH-RELATED QUALITY-OF-LIFE MEASURES: FIRST PRINCIPLES Erickson P, The On-Line Guide to Quality-of-Life Assessment (OLGA), and Department of Health Evaluation Sciences, Hershey Medical Center, Penn State University, State College, PA, USA
	WW15	PRODUCTIVITY RESEARCH: METHODOLOGIC APPROACHES AND ISSUES Stang P1, Greenberg P2, Kessler R3, 1Galt Associates Inc., Blue Bell, PA, USA; 2Analysis Group/Economics, Cambridge, MA, USA; 3Department of Health Care Policy, Harvard University Medical School, Boston, MA, USA
	WW16	THE USE OF INTEGER/LINEAR PROGRAMMING MODELS IN PHARMACOECONOMICS Earnshaw SR, Dennett SL, Richter A, Mauskopf JA, Research Triangle Institute, Research Triangle Park, NC, USA
5:30-6:30PM		ISPOR BUSINESS MEETING
6:30-8:00PM		EXHIBITORS OPEN HOUSE AND RECEPTION
8:00-10:00PM		COST-EFFECTIVENESS IN HEALTH AND MEDICINE PANEL DINNER (invitation only)